As the company faces increasing competition for its flagship product Eylea, it continues to leverage its strong research and development capabilities to expand its pipeline and explore new growth ...

The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

EYLEA HD (known as Eylea™ 8 mg in the European ... to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and ...

The trial, designed to compare the efficacy, safety, and immunogenicity of AVT06 with Eylea, reached the main goal, according to its topline data from January 2024. The duo said the FDA process to ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.